HPV Testing In Polish POpulation-based Cervical Cancer Screening Program. (HIPPOPROJECT)

  • days left to enroll
  • participants needed
  • sponsor
    Maria Sklodowska-Curie Institute - Oncology Center
Updated on 15 February 2022
cancer screening
diagnostic procedures
pap smear
cervical cancer screening
human papilloma virus vaccine
hpv test
screening method


The HIPPOPROJECT is a randomized healthcare study nested in the OCCSP in Poland. This project will assess the performance of the new screening test (HR HPV test) before its implementation in Poland.


The study assumes randomized assumption of 33,000 women aged 30-59 to cytology or HR HPV test in a 1:1 ratio with age stratification (three strata: 30-39, 40-49 and 50-59 years).

The study will start on September 2019 at the Department of Cervical Cancer Prevention at the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw. To obtain results representative for the entire country several sites are planned for inclusion in the study from 2020 in 10 regions of Poland.

Primary end-points include the detection rate of histologically confirmed high grade intraepithelial lesions or worse in each screening arm. Selected secondary endpoints include detection rate ratios, colposcopy referral rates and positive predictive values of referral for colposcopy.

Additionally, biobanking of cytological samples taken from patients participating in the HIPPO Project is planned in Maria Sklodowska-Curie National Research Institute of Oncology for the purpose of potential future restrospective analyses if new cervical cancer screening technologies emerge.

The study has been approved by a local bioethics committee.

Condition Cervical Cancer
Treatment Offering an alternative cervical cancer screening method - hrHPV molecular testing.
Clinical Study IdentifierNCT04111835
SponsorMaria Sklodowska-Curie Institute - Oncology Center
Last Modified on15 February 2022


Yes No Not Sure

Inclusion Criteria

women aged 30-59 with no screening Pap test within the preceding three years in the OCCSP and women with risk factors entitled to annual screening based on information from the SIMP and not tested within preceding 12 months (based on information from the screening database SIMP)

Exclusion Criteria

women with screening Pap test within the preceding three years in the OCCSP
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note